Liver Metastases Block Key Immune Cells That Fight Colorectal Cancer
New research reveals why colorectal cancer patients with liver metastases respond poorly to immunotherapy treatments.
Summary
Scientists discovered why colorectal cancer patients with liver metastases respond poorly to immunotherapy. The liver environment suppresses specialized immune cells called gamma-delta T cells that normally fight cancer. These immune cells depend on a protein called IL18 to function properly, but cancer cells in the liver produce IL18BP, which blocks this signal. When researchers prevented IL18BP from working, the immune cells became more effective at fighting cancer. This finding explains a major puzzle in cancer treatment and points toward new therapeutic approaches for patients whose cancer has spread to the liver.
Detailed Summary
This groundbreaking research solves a critical puzzle in cancer immunotherapy: why patients with liver metastases respond poorly to treatment. Understanding this mechanism could lead to more effective therapies for advanced colorectal cancer patients.
Researchers studied patients with mismatch repair-deficient colorectal cancers who had liver metastases. They analyzed immune cell populations and protein levels in tumor samples and blood from these patients compared to those without liver involvement.
The team discovered that liver metastases create an immunosuppressive environment by reducing gamma-delta T cells, specialized immune cells that produce interferon-gamma to fight cancer. These cells normally respond to IL18, a protein that activates immune responses. However, cancer cells counteract this by secreting IL18BP, which blocks IL18 signaling and dampens immune activity.
When researchers blocked IL18BP in laboratory experiments, gamma-delta T cells regained their cancer-fighting ability. Patients with liver metastases had elevated IL18 levels in their blood, and higher IL18 expression in tumors correlated with better immunotherapy responses specifically in this patient group.
For longevity and health optimization, this research highlights how cancer's ability to evade immune surveillance represents a fundamental aging-related process. The liver's unique immune environment makes it particularly vulnerable to metastatic colonization, explaining why liver involvement often signals poor prognosis across cancer types.
The study was limited to colorectal cancer patients and used primarily laboratory-based experiments. Clinical trials testing IL18BP inhibitors will be needed to confirm therapeutic potential in humans.
Key Findings
- Liver metastases reduce gamma-delta T cells that normally fight colorectal cancer
- Cancer cells produce IL18BP protein that blocks immune-activating IL18 signals
- Blocking IL18BP restores immune cell function against cancer in laboratory tests
- Patients with liver metastases have elevated IL18 levels in their bloodstream
- Higher tumor IL18 expression predicts better immunotherapy response in liver metastases
Methodology
Researchers analyzed tumor samples and blood from colorectal cancer patients with mismatch repair deficiency, comparing those with and without liver metastases. Laboratory experiments tested immune cell responses and IL18BP blocking effects on cancer organoids.
Study Limitations
The study focused specifically on mismatch repair-deficient colorectal cancers, limiting generalizability to other cancer types. Clinical trials are needed to validate IL18BP inhibition as an effective therapeutic strategy in humans.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.